Dompe Famaceutici S.p.A.
Via Santa Lucia, 6
6 articles with Dompe Famaceutici S.p.A.
Dompé Announces First Patient Enrollment in Phase 2b Clinical Trial Investigating Novel Mechanism of Action in Moderate to Severe Dry Eye Disease
Following the successful launch of Oxervate, the first-in-class recombinant human nerve growth factor (rhNGF) for treatment of neurotrophic keratitis (NK), Dompé embarks on a new clinical trial program to further investigate the relevance of treatment with rhNGF in Dry Eye Disease (DED).
Over the course of 2018, the FDA approved 59 different novel drugs that range for the treatment of various cancers, chronic obstructive pulmonary disease (COPD), traveler’s diarrhea, migraine headaches and more.
8/31/2018The U.S. Food and Drug Administration has had a busy August. In addition to the number of draft guidance documents the agency issued during the month, the FDA has also been busy approving a number of new treatments for a variety of diseases.
Dompe Famaceutici S.p.A. to Acquire 100% of Anabasis, an Italian Biopharmaceutical Ophthalmology Company
Dompe Famaceutici S.p.A. Release: New Frontier in the Treatment of Type 1 Diabetes -- Italian Researchers Present Findings in the Improvement of the Efficacy of Pancreatic Islet Transplantation